314 related articles for article (PubMed ID: 24047773)
1. [Anti-CCR4 mAb and regulatory T cells].
Kurose K; Ohue Y; Oka M
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
[TBL] [Abstract][Full Text] [Related]
2. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
Remer M; Al-Shamkhani A; Glennie M; Johnson P
Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
[TBL] [Abstract][Full Text] [Related]
3. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
[TBL] [Abstract][Full Text] [Related]
4. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.
Chang DK; Sui J; Geng S; Muvaffak A; Bai M; Fuhlbrigge RC; Lo A; Yammanuru A; Hubbard L; Sheehan J; Campbell JJ; Zhu Q; Kupper TS; Marasco WA
Mol Cancer Ther; 2012 Nov; 11(11):2451-61. PubMed ID: 22869555
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma.
Watanabe Y; Katou F; Ohtani H; Nakayama T; Yoshie O; Hashimoto K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):744-52. PubMed ID: 20303300
[TBL] [Abstract][Full Text] [Related]
6. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
[TBL] [Abstract][Full Text] [Related]
7. Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.
Kurose K; Ohue Y; Wada H; Iida S; Ishida T; Kojima T; Doi T; Suzuki S; Isobe M; Funakoshi T; Kakimi K; Nishikawa H; Udono H; Oka M; Ueda R; Nakayama E
Clin Cancer Res; 2015 Oct; 21(19):4327-36. PubMed ID: 26429981
[TBL] [Abstract][Full Text] [Related]
8. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
9. [Basic and clinical evaluation of anti-CCR4 mAb in cancer immunotherapy].
Oka M; Kurose K
Nihon Rinsho; 2017 Feb; 75(2):209-215. PubMed ID: 30562854
[TBL] [Abstract][Full Text] [Related]
10. Tumors establish resistance to immunotherapy by regulating T
Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
[TBL] [Abstract][Full Text] [Related]
11. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
[TBL] [Abstract][Full Text] [Related]
12. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.
Ishida T; Ishii T; Inagaki A; Yano H; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Res; 2006 Jun; 66(11):5716-22. PubMed ID: 16740709
[TBL] [Abstract][Full Text] [Related]
13. Immunopathogenesis of lymphoma: focus on CCR4.
Ishida T; Ueda R
Cancer Sci; 2011 Jan; 102(1):44-50. PubMed ID: 21044233
[TBL] [Abstract][Full Text] [Related]
14. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma.
Ishida T; Iida S; Akatsuka Y; Ishii T; Miyazaki M; Komatsu H; Inagaki H; Okada N; Fujita T; Shitara K; Akinaga S; Takahashi T; Utsunomiya A; Ueda R
Clin Cancer Res; 2004 Nov; 10(22):7529-39. PubMed ID: 15569983
[TBL] [Abstract][Full Text] [Related]
15. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
[TBL] [Abstract][Full Text] [Related]
16. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
17. CCR4 and its ligands: from bench to bedside.
Yoshie O; Matsushima K
Int Immunol; 2015 Jan; 27(1):11-20. PubMed ID: 25087232
[TBL] [Abstract][Full Text] [Related]
18. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
Ishii T; Ishida T; Utsunomiya A; Inagaki A; Yano H; Komatsu H; Iida S; Imada K; Uchiyama T; Akinaga S; Shitara K; Ueda R
Clin Cancer Res; 2010 Mar; 16(5):1520-31. PubMed ID: 20160057
[TBL] [Abstract][Full Text] [Related]
19. Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis.
Watanabe M; Kanao K; Suzuki S; Muramatsu H; Morinaga S; Kajikawa K; Kobayashi I; Nishikawa G; Kato Y; Zennami K; Nakamura K; Tsuzuki T; Yoshikawa K; Ueda R; Sumitomo M
Prostate; 2019 Oct; 79(14):1658-1665. PubMed ID: 31390096
[TBL] [Abstract][Full Text] [Related]
20. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]